Metsera (MTSR) Proxy Filing summary

Executive summary

• Litigation initiated by Pfizer against the company is ongoing, with the company publicly disputing Pfizer's claims and affirming its commitment to shareholders and patients.

• Pfizer's proposed acquisition of the company is subject to significant risks, including litigation, regulatory approvals, and competing offers, notably from Novo Nordisk.

• Forward-looking statements highlight uncertainties regarding the timing and completion of the acquisition, integration challenges, and potential impacts on business operations and stock price.

Voting matters and shareholder proposals

• Stockholders are being asked to vote on the proposed acquisition by Pfizer, with proxy statements mailed and available for review.

• Investors are urged to base voting decisions solely on the information in the definitive proxy statement.

Board of directors and corporate governance

• The board is actively engaged in defending the company's interests in litigation and in the acquisition process.

• Directors, executive officers, and management may be considered participants in the proxy solicitation for the proposed transaction.